Nurix Therapeutics Inc - ESG Rating & Company Profile powered by AI
This page contains a zero-cost E,S&G report for Nurix Therapeutics Inc. The Sustainability rating for Nurix Therapeutics Inc indicates its transparency towards the United Nations SDGs. Complete Sustainability assessment of Nurix Therapeutics Inc can be accessed by registering for free.
Nurix Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 3.2, social score of 8.0 and governance score of 8.0.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 511 | Wakamoto Pharmaceutical Co Ltd | 6.5 | High |
| 511 | X4 Pharmaceuticals Inc | 6.5 | High |
| 535 | Nurix Therapeutics Inc | 6.4 | High |
| 535 | Al Mansour Pharmaceuticals Industries Co | 6.4 | High |
| 535 | Alpine Immune Sciences Inc | 6.4 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Nurix Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Nurix Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Nurix Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Nurix Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Nurix Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Nurix Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Nurix Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Nurix Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Nurix Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Nurix Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Nurix Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Nurix Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Nurix Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Nurix Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Nurix Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Nurix Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Nurix Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Nurix Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.